For research use only. Not suitable for human use.
Isotype
IgG1, kappa
Clonality
Monoclonal Antibody
Description of Obinutuzumab Biosimilar - Anti-MS4A1, CD20 mAb - Research Grade
General information on Anti-MS4A1/CD20(Homo sapiens) (Obinutuzumab) Monoclonal Antibody
Obinutuzumab is a humanized monoclonal antibody that can be used in combination with chlorambucil to treat chronic lymphocytic leukemia. It was sold under the Gazyva brand. There are black box warnings of fatal hepatitis B virus (HBV) reactivation and fatal progressive multifocal leukoencephalopathy (PML).
Obinutuzumab Biosimilar - Anti-MS4A1, CD20 mAb - Research Grade binds to Human CD20/MS4A1 recombinant protein in ELISA assay
Immobilized Human CD20/MS4A1 recombinant protein (cat. No.PX-P6274) at 0.5µg/mL (100µL/well) can bind Obinutuzumab Biosimilar - Anti-MS4A1, CD20 mAb - Research Grade (cat. No.PX-TA1172) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450 giving an EC50 at 134.2M.
SDS-PAGE for Obinutuzumab Biosimilar - Anti-MS4A1, CD20 mAb - Research Grade
Obinutuzumab Biosimilar - Anti-MS4A1, CD20 mAb - Research Grade on SDS-PAGE under reducing and non-reducing conditions. The gel was stained overnight with Coomassie Blue.. The purity of the antibody is greater than 95%.
Publication
Joshua S. Bray, Gethin R. Thomas, Victoria M. Smith, Sandrine Jayne, Martin J.S. Dyer, Harriet S. Walter, Comparative in-Vitro Efficacy of CD20xCD3 IgG Bispecific Biosimilar Constructs Against Diffuse Large B Cell Lymphoma (DLBCL) Cell Lines with Different Levels of Expression of CD20, Blood, Volume 144, Supplement 1, 2024, Page 5826, ISSN 0006-4971, https://doi.org/10.1182/blood-2024-203884.
Reviews
There are no reviews yet.
REVIEW YOUR PRODUCT
Be the first to review “Obinutuzumab Biosimilar – Anti-MS4A1, CD20 mAb – Research Grade” Cancel reply
Reviews
There are no reviews yet.